• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   Open Access Home
  • Rektörlüğe Bağlı Bölümler
  • Araştırma Çıktıları
  • Öksüz Yayınlar Koleksiyonu - WoS
  • View Item
  •   Open Access Home
  • Rektörlüğe Bağlı Bölümler
  • Araştırma Çıktıları
  • Öksüz Yayınlar Koleksiyonu - WoS
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology

Date

2014

Author

Duran, Ayse Ocak
Karaca, Halit
Besiroglu, Mehmet
Bayoglu, Ibrahim Vedat
Menekse, Serkan
Yapici, Heves Surmeli
Yazilitas, Dogan
Bahceci, Aykut
Uysal, Mukremin
Sevinc, Alper
Hacibekiroglu, Ilhan
Aksoy, Asude
Tanriverdi, Ozgur
Arpaci, Erkan
Inanc, Mevlude
Dane, Faysal
Ozkan, Metin

Metadata

Show full item record

Abstract

Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95% CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95% CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95% CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95% CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.

Source

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION

Volume

15

Issue

23

URI

https://dx.doi.org/10.7314/APJCP.2014.15.23.10375
https://hdl.handle.net/20.500.12418/8355

Collections

  • Makale Koleksiyonu [5200]
  • Makale Koleksiyonu [5745]
  • Öksüz Yayınlar Koleksiyonu - WoS [6162]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




Open Access Policy
About Open Access
User Guide
Contact

DSpace@Cumhuriyet

by OpenAIRE
Advanced Search

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherCategoryLanguageAccess TypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherCategoryLanguageAccess Type

My Account

LoginRegister

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Sivas Cumhuriyet University || Library || Open Access Policy || About Open Access || User Guide || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, Sivas, Turkey
If you find any errors in content, please contact: acikerisim-yardim@cumhuriyet.edu.tr

Creative Commons License
DSpace@Cumhuriyet by Sivas Cumhuriyet University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

Sivas Cumhuriyet University is a member of the following institutions.


DSpace 6.3

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.